Mycetoma Investigational Drug

About Eisai

Eisai is a fully integrated, patient-centric biopharmaceutical company with a mission to give first thought to patients and their families. Its strategic focus on neurology and oncology has yielded landmark achievements, most notably the commercialization of the first disease-modifying Alzheimer's therapy, LEQEMBI, in partnership with Biogen. The company complements its commercial success with a deep, long-standing commitment to sustainability and global health, distributing billions of treatments for neglected tropical diseases. Financially robust and strategically disciplined, Eisai is leveraging its neuroscience leadership to expand its oncology portfolio and solidify its long-term growth trajectory.

Therapeutic Areas